Australia Questions Soliris Survival Benefit; Adds Listings From MSD, Novartis, Janssen To PBS
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Australia's Minister of Health Nicola Roxon requested advice from the Pharmaceutical Benefits Advisory Committee on the potential benefits of adding Alexion's Soliris (eculizumab) to the government's Life Saving Drugs Program (LSDP)
You may also be interested in...
More Oncology Drugs Available In U.S. But Australians Pay 30% Less - Tufts Study
PERTH, Australia - Oncology drug prices in Australia were roughly 30 percent lower than in the U.S. over the past decade, thanks to comparative effectiveness policies imposed by Australia's Pharmaceutical Benefits Scheme, according to a recent study conducted by the Tufts Center for the Study of Drug Development
More Oncology Drugs Available In U.S. But Australians Pay 30% Less - Tufts Study
PERTH, Australia - Oncology drug prices in Australia were roughly 30 percent lower than in the U.S. over the past decade, thanks to comparative effectiveness policies imposed by Australia's Pharmaceutical Benefits Scheme, according to a recent study conducted by the Tufts Center for the Study of Drug Development
More Oncology Drugs Available In U.S., But Australians Pay 30% Less - Tufts Study
The evidence-based approach adopted by Australia has led to lower prices, improving the affordability of those medications considered cost-effective for payers and patients by the reimbursement authority, the report says.